UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 12, 2010

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756 (Commission File Number)

Delaware (State or Other Jurisdiction of Incorporation) 94-3023969 (I.R.S. Employer Identification No.)

932 Southwood Boulevard Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On May 12, 2010, PDL BioPharma, Inc. (the "Company") will make a presentation at the Ninth Annual JMP Securities Research Conference in San Francisco, California. A copy of the Company's presentation materials has been posted to the Company's website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company's royalty assets or business are disclosed in the "Risk Factors" contained in the Company's 2009 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2010. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1 Presentation at Ninth Annual JMP Securities Research Conference on May 12, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ Christine R. Larson Christine R. Larson

Vice President and Chief Financial Officer

Dated: May 12, 2010

EXHIBIT INDEX

Exhibit No.

99.1


 Description

 Presentation at Ninth Annual JMP Securities Research Conference on May 12, 2010



Ninth Annual JMP Securities Research Conference

May 12, 2010



Key Information

 Company: 	PDL BioPharma	
 Ticker: 	PDLI (NASDAQ)	
 Location: 	Incline Village, Nevada	
 Employees: 	Less than 10	
• 2009 Revenues:	\$318 million	
• 2009 Expenses:	\$21 million	
• 2009 Dividends:	\$0.50/sh, \$0.50/sh, \$1.67/sh	
 2010 Dividends: 	\$0.50/share on April 1 ^{st1} and \$0.50/share on October 1 ^{st2}	
 Shares O/S³: 	119,526,000	
 Avg. Daily Vol.: 	~3 million shares	
1. Record holders as of Ma	rch 15 th ; 2. Record holders as of September 15 th ; 3. Not fully diluted.	BioP



Forward Looking Statements

This presentation contains forward-looking statements, including PDL's expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

•The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;

- The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
- The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
- Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
- The outcome of pending litigation, interferences or disputes; and
- The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forwardlooking statements in this presentation are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at <u>www.pdl.com</u>. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement.



- Overview of PDL BioPharma
- Royalty revenue & licensed products
- Optimizing stockholder return



Overview of PDL BioPharma



Company Background

- PDL pioneered the humanization of monoclonal antibodies which enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases
- PDL's primary assets are its antibody humanization patents and royalty assets which consist of its Queen et al. patents and license agreements
- Licensees consist of large biotechnology and pharmaceutical companies including Roche/Genentech/ Novartis, Elan/BiogenIDEC, Pfizer/Wyeth/J&J and Chugai



Mission

- Manage patent portfolio
- Manage license agreements
- Optimize return for shareholders



2009 Performance

- PDL is a highly profitable company with revenue in 2009 in of \$318 million and fewer than 10 employees
- PDL is domiciled in state of Nevada in US where there is no state corporate income tax
- PDL's mission is to improve shareholder return
 - We paid three dividends of \$0.50/share in April, \$0.50/share in October and \$1.67/share in December totaling \$2.67 in 2009
 - Our goal is to pay dividends annually & we have declared two dividends of \$0.50 each/share in 2010
 - We signed one new license under the Queen et al. patents in 2009 and are seeking new licenses in 2010
 - We do <u>not</u> invest in R&D or in operating companies



Corporate Governance

Management

- John McLaughlin President & CEO
- Christine Larson
 VP & CFO
- Christopher Stone VP, General Counsel & Secretary
- Karen Wilson
 VP of Finance

Board of Directors


- Fred Frank
 Lead Director
- Joseph Klein
- Jody Lindell
- John McLaughlin
- Paul Sandman
- Harold Selick



Royalty Revenue & Licensed Products



Royalty Revenue & Licensed Products




BioPharma*

- PDL's revenues consist of royalties generated on sales of licensed products
 - Sold before the expiration of the Queen et al. patents in 2013/14

or

Made prior to the expiration of the Queen et al. patents and sold anytime thereafter



Genentech/Roche Royalties *

Product Made in US	
Net Sales up to \$1.5 Billion	3.0%
Net Sales Between \$1.5 Billion and \$2.5 Billion	2.5%
Net Sales Between \$2.5 Billion and \$4.0 Billion	2.0%
Net Sales Over \$4.0 Billion	1.0%
Product Made and Sold Ex-US	
All Sales	3.0%

^{*} Excludes royalties for Actemra / RoActemra

- In 2009, only <u>12%</u> of Genentech/Roche sales was ex-US manufactured and sold product
- In Q1-2010, <u>19%</u> of Genentech/Roche sales was ex-US manufactured and sold product
- Average royalty rate on all Genentech/Roche products under Genentech license was 1.69% in 2009




Genentech/Roche—Future Manufacturing

Roche has begun to move some manufacturing ex-US

- Two new plants in Singapore (CHO = antibody and e. coli = antibody fragment)
 E. coli (Lucentis) to transfer to Singapore in 2011/12
- Production at Penzburg (Herceptin) and Basel (Avastin) plants

Roche says it will complete global restructuring of manufacturing in 2010



Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric Prostate Cancer Adjuvant settings
	Herceptin	Approved	Breast HER2+ Cancer HER2+ Stomach and Gastro-Esophageal Cancers
	trastuzumab-DM1	Phase 2 and 3	Breast HER2+ Cancer
	Lucentis	Approved Phase 3	AMD RVO DME
	Xolair	Approved sBLA	Moderate-Severe Asthma Pediatric Asthma
Elan	Tysabri	Approved	Multiple Sclerosis
Roche/Chugai	Actemra	Approved	Rheumatoid Arthritis
Wyeth	Mylotarg	Approved	Acute Myeloid Leukemia
Elan/J&J/Pfizer	Bapineuzumab	Phase 3	Alzheimer's Disease
Lilly	Solanezumab	Phase 3	Alzheimer's Disease
	Teplizumab	Phase 3	Newly Diagnosed Type 1 Diabetes

Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric Prostate Cancer Adjuvant settings
	Herceptin	Approved	Breast HER2+ Cancer HER2+ Stomach and Gastro-Esophageal cancers
	trastuzumab-DM1	Phase 2 and 3	Breast HER2+ Cancer
	Lucentis	Approved	AMD
stomach or g Expect Ela On Jar	, Genentech filed sBl gastro-esophageal jur ted PDUFA date is Fr nuary 28 th , Roche anr	LA with FDA for fin action cancers. iday, October 22, nounced EU appro	rst line treatment of HER2-positive
stomach or g Expect Ela On Jar Rod treatm	d, Genentech filed sBl gastro-esophageal jur ted PDUFA date is Fr nuary 28 th , Roche anr ent of HER-2 positive	LA with FDA for fin nction cancers. iday, October 22, nounced EU appro- stomach or gastr	2010. 2010. 2010. Eval for the use of Herceptin first line o-esophageal junction cancers.
stomach or g Expect Ela On Jar Roc treatm	d, Genentech filed sBl gastro-esophageal jur ted PDUFA date is Fr nuary 28 th , Roche ann ent of HER-2 positive	LA with FDA for fin nction cancers. iday, October 22, nounced EU appro stomach or gastr	rst line treatment of HER2-positive 2010. oval for the use of Herceptin first line o-esophageal junction cancers.

Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric Prostate Cancer Adjuvant settings
	Herceptin	Approved	Breast HER2+ Cancer HER2+ Stomach and Gastro-Esophageal Cancers
	trastuzumab-DM1	Phase 2 and 3	Breast HER2+ Cancer
	Lucentis	Approved	AMD
✓ After meeting in 2010.	Lucentis	Approved	
	Lucentis	Approved	AMD
in 2010.	Lucentis with FDA, Roche has	Approved	AMD pects to file a BLA for third line treatment
in 2010. Elan	Lucentis with FDA, Roche has Tysabri	Approved confirmed that it ex Approved	AMD pects to file a BLA for third line treatment Multiple Sclerosis
in 2010. Elan Roche/Chugai	Lucentis with FDA, Roche has Tysabri Actemra	Approved confirmed that it ex Approved Approved	AMD pects to file a BLA for third line treatment Multiple Sclerosis Rheumatoid Arthritis
in 2010. Elan Roche/Chugai Wyeth	Lucentis with FDA, Roche has Tysabri Actemra Mylotarg	Approved confirmed that it ex Approved Approved Approved	AMD pects to file a BLA for third line treatment Multiple Sclerosis Rheumatoid Arthritis Acute Myeloid Leukemia

icensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric
			nentech 's sBLA to the FDA for tinal vein occlusion (RVO).
	Lucentis	Approved	AMD
	Lucentia	Phase 3	RVO DME
	Xolair		RVO
Elan		Phase 3	RVO DME Moderate-Severe Asthma
	Xolair	Phase 3 Approved sBLA	RVO DME Moderate-Severe Asthma Pediatric Asthma
Elan Roche/Chugai Wyeth	Xolair Tysabri	Phase 3 Approved sBLA Approved	RVO DME Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis
Roche/Chugai	Xolair Tysabri Actemra	Phase 3 Approved sBLA Approved Approved	RVO DME Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis Rheumatoid Arthritis
Roche/Chugai Wyeth	Xolair Tysabri Actemra Mylotarg	Phase 3 Approved SBLA Approved Approved Approved	RVO DME Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis Rheumatoid Arthritis Acute Myeloid Leukemia

Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved	Colorectal Cancer NSCLC
therapy with o (DME) that sh improvement	r without Lucentis or a owed eyes treated wit	a corticosteroid in th Lucentis plus la	d data from a Phase 3 trial of laser patients with diabetic macular edema ser therapy had a significant uity (BCVA) score from baseline vs.
			RER2+ Stomach and Gastro-Esophageal Cancers
	trastuzumab-DM1	Phase 2 and 3	Breast HER2+ Cancer
	Lucentis	Approved Phase 3	AMD RVO DME
	Xolair	Approved sBLA	Moderate-Severe Asthma Pediatric Asthma
Elan	Tysabri	Approved	Multiple Sclerosis
Roche/Chugai	Actemra	Approved	Rheumatoid Arthritis
Wyeth	Mylotarg	Approved	Acute Myeloid Leukemia
	Deningenerati	Phase 3	Alzheimer's Disease
Elan/J&J/Pfizer	Bapineuzumab		
Elan/J&J/Pfizer Lilly	Solanezumab	Phase 3	Alzheimer's Disease

_icensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric Prostate Cancer Adjuvant settings
	Hercentin	Approved	Breast HER2+ Cancer
antibody pos	itivity and development		o measure the correlation of JCV
antibody pos	-		o measure the correlation of JCV
antibody pos	itivity and development		
antibody pos	itivity and development pected in 2H-2010.	t of PML.	DML Moderate-Severe Asthma
antibody pos ✓Data is exp	itivity and development bected in 2H-2010.	Approved sBLA	Moderate-Severe Asthma Pediatric Asthma
antibody pos ✓Data is exp Elan	itivity and development bected in 2H-2010. Xolair Tysabri	Approved sBLA Approved	Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis
antibody pos ✓Data is exp Elan Roche/Chugai	itivity and development pected in 2H-2010. Xolair Tysabri Actemra	Approved sBLA Approved Approved	Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis Rheumatoid Arthritis
antibody pos ✓ Data is exp Elan Roche/Chugai Wyeth	itivity and development bected in 2H-2010. Xolair Tysabri Actemra Mylotarg	Approved sBLA Approved Approved Approved	Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis Rheumatoid Arthritis Acute Myeloid Leukemia

Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Motastatic Ronal Coll
approval fro progression	m the European Medi	cines Agency to e mprove physical f	has received a recommendation for xtend its indication to reduce the rate of unction in patients with rheumatoid otrexate.
claims for th	e prevention of struct	ural joint damage	ad been submitted to FDA to include (as assessed by radiograph) and lerately to severely active RA.
claims for th	e prevention of struct	ural joint damage	(as assessed by radiograph) and
claims for th	e prevention of struct	ural joint damage	(as assessed by radiograph) and
claims for th	e prevention of struct ht in physical function	ural joint damage in adults with moo Approved	(as assessed by radiograph) and lerately to severely active RA. Moderate-Severe Asthma
claims for th improvemen	t prevention of struct t in physical function Xolair	ural joint damage in adults with mod Approved sBLA	(as assessed by radiograph) and lerately to severely active RA. Moderate-Severe Asthma Pediatric Asthma
claims for th improvemen	Xolair Tysabri	ural joint damage in adults with mod Approved sBLA Approved	(as assessed by radiograph) and lerately to severely active RA. Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis
Claims for the improvement of the improvement of the second secon	Xolair Tysabri Actemra	ural joint damage in adults with mod Approved sBLA Approved Approved	(as assessed by radiograph) and lerately to severely active RA. Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis Rheumatoid Arthritis
claims for th improvemen Elan Roche/Chugai	Prevention of struct tin physical function Xolair Tysabri Actemra Mylotarg	Approved Approved SBLA Approved Approved Approved	(as assessed by radiograph) and lerately to severely active RA. Moderate-Severe Asthma Pediatric Asthma Multiple Sclerosis Rheumatoid Arthritis Acute Myeloid Leukemia

Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric Prostate Cancer Adjuvant settings
	Herceptin	Approved	Breast HER2+ Cancer
			patients with Alzheimer's disease were
reported in brain from patients. ✓ J&J anticip	Lancet Neurology whi a baseline in treated pa	ch showed 9% re atients compared erican pivotal stu	patients with Alzheimer's disease were duction in amyloid-beta deposits on the to a plaque increase of 15% in placebo dies of bapineuzumab will be completed
reported in brain from patients. ✓ J&J anticip with the las	Lancet Neurology white a baseline in treated parameters the two North Am	ch showed 9% re atients compared erican pivotal stu	duction in amyloid-beta deposits on the to a plaque increase of 15% in placebo
reported in brain from patients. ✓ J&J anticip with the las	Lancet Neurology white a baseline in treated parates the two North Am t patient out in mid-20	ch showed 9% re atients compared erican pivotal stu 12.	duction in amyloid-beta deposits on the to a plaque increase of 15% in placebo dies of bapineuzumab will be completed
reported in brain from patients. ✓ J&J anticip with the las Roche/Chugai Wyeth	Lancet Neurology white a baseline in treated para ates the two North Am t patient out in mid-20 Actemra	ch showed 9% re atients compared erican pivotal stu- 12. Approved	duction in amyloid-beta deposits on the to a plaque increase of 15% in placebo dies of bapineuzumab will be completed Rheumatoid Arthritis
reported in brain from patients. ✓ J&J anticip with the las Roche/Chugai	Lancet Neurology white a baseline in treated parates the two North Am t patient out in mid-20 Actemra Mylotarg	ch showed 9% re atients compared erican pivotal stu- 12. Approved Approved	duction in amyloid-beta deposits on the to a plaque increase of 15% in placebo dies of bapineuzumab will be completed Rheumatoid Arthritis Acute Myeloid Leukemia

Licensee	Product	Status	Indications
Roche (Genentech)	Avastin	Approved Phase 3	Colorectal Cancer NSCLC Metastatic Breast Cancer Glioblastoma Metastatic Renal Cell Ovarian Cancer Gastric Prostate Cancer Adjuvant settings
	Herceptin	Approved	Breast HER2+ Cancer HER2+ Stomach and Gastro-esophagel Cancers
	trastuzumab-DM1	Phase 2 and 3	Breast HER2+ Cancer
	Lucentis	Approved Phase 3	AMD RVO DME
Ela second stue	in one of the Phase 3 s dy is closing in on 50% ted in mid-2012.		zumab has exceeded 50% while the
Elan/J&J/Pfizer	Bapineuzumab	Phase 3	Alzheimer's Disease
Lilly	Solanezumab	Phase 3 🏾 🌥	Alzheimer's Disease

Genentech/Roche—Future Products

- In December 2008, Genentech exercised options for 4 additional antigens and extended other options paying fees totaling \$1.8 million
- Genentech can seek to convert the exercised options into license agreements by identifying the target antigen so long as certain other conditions are met
- Genentech/Roche has a number of humanized antibodies in Phase 3
 - Pertuzumab: HER2+ breast cancer Phase 3 started in Q1-2008
 - GA101: CLL, NHL Phase 3 started in Q4-2009
 - Ocrelizumab: RA Positive Phase 3 in Q4-2009, methotrexate naive and TNF inadequate responders in 2010 <u>but</u> Roche/BIIB announced on March 8th suspension of RA trials based on safety concerns raised by DSMB; now appear to be focusing on multiple sclerosis
 - Lebrikizumab: Phase 2 asthma, identified by Roche as possible Phase 3 in 2010 with possible filing in 2013

24

Genentech / Roche – US & EU Filings

2009	2010	2011	2012
Avastin + docetaxel mBC 1L (US)	Avastin mBC 2L	Avastin Recurrent ovarian ca platinum sensitive	Avastin BC adj HER2-
Avastin +STD chemo mBC 1L	Avastin CC adj	Avastin + Herceptin mBC HER2+ 1L	Herceptin SC formulation (EU)
Herceptin Gastric ca HER+ (EU)	Avastin Ovarian ca 1L	Pertuzumab ¹ mBC HER2+	GA 101 ¹ CLL
Lucentis Retinal vein occlusion (US)	Herceptin Gastric ca HER2+ (US)	Lucentis Diabetic macular edema (US)	T-DM1 mBC HER2+ 2L
	T-DM1 mBC HER2+ 3L (US)		Actemra subcutaneous
	Avastin Herceptin Lucentis T-DM1	Actemra Pertuzumab ¹ GA-101 ¹ t a licensed product	SioPharm

Legal Matters and Debt



Genentech

- In 2003, settlement agreement resolved all disputes regarding infringement of the Genentech products and the validity and enforceability of our patents
- Multiple product licenses with tiered royalty structure
- Alexion
 - Settlement in December 2008 stipulated infringement, validity and enforceability of PDL patents and no future contest of PDL patents
 - License for Soliris in exchange for \$25 million and option for 4 new licenses at 4% royalty

MedImmune

- In 2008, MEDI initiated litigation seeking declaratory judgment of patent invalidity and non-infringement and a lower royalty rate based on its "most favored licensee" (MFL) rights
 - PDL believes that it has no obligation to offer a lower royalty rate to MEDI under the MFL clause
- PDL is suing MEDI for patent infringement because PDL has cancelled the MEDI license agreement due to MEDI's failure to pay all royalties due and blockage of PDL's exercise of its contractual rights
- Trial in January 2011

UCB/Celltech

- US Patent Office has declared two interference proceedings between certain claims of Queen et al. patents and pending claims of Adair et al. patent
- UCB/Celltech is the assignee of the Adair et al. patent



\$200 million 2.75% convertible subordinated notes due August 2023

- Repurchased \$50 million in 2009 and \$84 million in Q2-2010
- Conversion rate is 177.1594 shares / \$1,000 face amount (\$5.64/share)
- Holders have a put right in August 2010, August 2013, and August 2018
- August 2010 put can be for cash or stock, at noteholders' discretion
 - Subsequent puts are cash or stock at PDL's discretion
- Price as of May 8th was ~ 111 vs. stock price of \$5.90

\$228 million 2.00% convertible senior notes due February 2012

- Repurchased \$22 million in 2009
- Conversion rate is 128.318 shares / \$1,000 face amount (\$7.79/share)
- Price as of May 8th was ~ 95 vs. stock price of \$5.90

\$300 million 10.25% note with expected maturity of December 2012

- Securitized by 60% of 5-year NPV of Genentech royalties
- Anticipated final maturity is December 2012; legal maturity is March 2015
- After final maturity, securitized Genentech royalties return to PDL
- Distributed \$200 million as special dividend of \$1.67/share in December 2009
- Retained \$100 million for royalty purchases



Optimizing Stockholder Return



- Continuously evaluating alternatives
 - Dividends
 - Purchase of commercial stage, royalty generating assets
 - Convertible note buyback
 - Bought back \$84 million worth of 2023 Notes to increase shareholder return in Q2-2010
 - Share repurchase
 - Company sale
 - Do not expect to securitize any more assets in 2010



High Dividend Yield with Upside Optionality

- Inventory on hand at Queen et al. patent expiry 12/2014
- Change in manufacturing US / ex-US mix for Roche/Genentech resulting in higher average royalty rates
- New Phase 2/3 indications with existing commercial products
- Phase 2/3 pipeline products
 - Solanezumab (Alzheimer's disease)
 - Bapineuzumab (Alzheimer's disease)
 - Teplizumab (newly diagnosed Type 1 Diabetes)
- New product licenses
 - Genentech exercised 4 options in December 2008
 - New licensees
- Purchase new, high-yielding royalty assets



Investment Rationale

- Strong revenue growth from approved products
- Potential for additional indications from existing products, new product approvals and new royalty assets
- Significantly reduced expenses with no R&D burn
- Liquidity volume averages 3 million shares / day
- Return to stockholders
 - Declared three special cash dividends totaling \$2.67/share in 2009
 - Paid special cash dividend of \$0.50/share on April 1st
 - Will pay special cash dividend of \$0.50/share on October 1st

